EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

Masahiro Tsuboi, Roy S Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W Goldman iD, Shun Lu, Wu-Chou Su, Filippo de Marinis, Frances A Shepherd und 9 weitere

New England Journal of Medicine · 13.07.2023 · 389 (2) · 137-147

DOI: 10.1056/nejmoa2304594 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 13.07.2023. Verfasst von Masahiro Tsuboi und 20 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), the Department of Thoracic Oncology, Kana…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, COVID-19, Lung Neoplasms. Die Arbeit wurde bisher 699-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCOVID-19Lung NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsErbB ReceptorsMutationNeoplasm Recurrence, LocalSurvival AnalysisAcrylamidesAniline CompoundsIndolesPyrimidines

Substanzen

ErbB ReceptorsEGFR protein, humanosimertinibAcrylamidesAniline CompoundsIndolesPyrimidines

Autor:innen und Institutionen

  • From the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) - both in Japan; the Section of Me…

ORCID-Profile: Jonathan W Goldman

Förderung

  • AstraZeneca

Zitieren

APA

Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lu, S., Su, W. C., de Marinis, F., Shepherd, F. A., Lee, K. H., Le, N. T., Dechaphunkul, A., Kowalski, D., Poole, L., Bolanos, A., Rukazenkov, Y., …, & ADAURA Investigators (2023). Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC. New England Journal of Medicine, 389(2), 137-147. https://doi.org/10.1056/nejmoa2304594

Vancouver

Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, et al. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC. New England Journal of Medicine. 2023;389(2):137-147. doi:10.1056/nejmoa2304594

BibTeX
@article{Tsuboi2023,
  author = {Tsuboi, Masahiro and Herbst, Roy S and John, Thomas and Kato, Terufumi and Majem, Margarita and Grohé, Christian and Wang, Jie and Goldman, Jonathan W and Lu, Shun and Su, Wu-Chou and de Marinis, Filippo and Shepherd, Frances A and Lee, Ki Hyeong and Le, Nhieu Thi and Dechaphunkul, Arunee and Kowalski, Dariusz and Poole, Lynne and Bolanos, Ana and Rukazenkov, Yuri and Wu, Yi-Long and ADAURA Investigators, ADAURA Investigators},
  title = {Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {2},
  pages = {137--147},
  doi = {10.1056/nejmoa2304594}
}
Kostenlos starten →